96912

Photochemotherapy; psoralens and ultraviolet A (PUVA)

Photochemotherapy utilizing psoralens and ultraviolet A (UVA) light, commonly known as PUVA therapy, is a highly effective, specialized dermatological treatment represented by CPT code 96912. This therapeutic approach leverages the potent synergistic effects of a photosensitizing agent (psoralen) and long-wave ultraviolet A radiation to manage severe, recalcitrant inflammatory and proliferative skin dermatoses. It is most frequently indicated for severe plaque psoriasis, cutaneous T-cell lymphoma (such as mycosis fungoides), severe atopic dermatitis, widespread vitiligo, and lichen planus. The mechanism of action is deeply antiproliferative and profoundly immunosuppressive. Psoralens are naturally occurring or synthetic organic compounds that rapidly intercalate into the DNA of epidermal cells. When subsequently exposed to UVA light, the psoralen molecules absorb the photons and form covalent cross-links with the DNA pyrimidine bases. This precise photochemical reaction dramatically inhibits DNA synthesis, directly halting the rapid hyperproliferation of keratinocytes that characterizes psoriasis. Furthermore, PUVA induces localized apoptosis of pathogenic T-lymphocytes within the skin, substantially reducing the inflammatory cascade. The procedure requires rigorous clinical supervision and precise dosimetry. Psoralens can be administered systemically (orally) or topically (via soaking in a psoralen bath or direct application). After a carefully timed absorption period, which is typically one to two hours for oral administration to reach peak cutaneous photosensitivity, the patient is placed in a specially designed UVA phototherapy cabin. The UVA dose is meticulously calibrated in Joules per square centimeter based on the patient's skin phototype and previous treatment response to prevent severe phototoxic erythema (severe burns). Comprehensive eye protection using UVA-blocking goggles is absolutely mandatory during the session and for up to 24 hours post-treatment due to the risk of psoralen-induced cataracts. PUVA therapy demands a significant commitment, usually requiring sessions two to three times per week. Because of the intensive nature and the associated risks, such as long-term photoaging and an increased incidence of non-melanoma skin cancers (particularly squamous cell carcinoma), it is typically reserved for patients who have failed more conservative therapies like narrow-band UVB. CPT code 96912 strictly encompasses the photochemotherapy administration and the UVA exposure.

Clinical Indications

  • Severe, treatment-resistant plaque psoriasis
  • Cutaneous T-cell lymphoma (e.g., Mycosis fungoides, Sézary syndrome)
  • Widespread or generalized vitiligo
  • Severe atopic dermatitis (eczema) refractory to standard care
  • Lichen planus
  • Polymorphous light eruption (prophylactic hardening)
  • Alopecia areata

Procedure Steps

  1. Clinical evaluation of the patient's current skin status, assessing for excessive erythema, blistering, or phototoxicity from previous PUVA sessions.
  2. Administration of the psoralen photosensitizer either orally (e.g., methoxsalen) 1.5 to 2 hours prior to light exposure, or topically via a targeted bath or localized soak.
  3. Verification that the patient is wearing comprehensive UVA-blocking protective eyewear to prevent cataract formation, as well as genital shielding for male patients.
  4. Calculation of the appropriate UVA dosimetry (in Joules per square centimeter) based on minimal phototoxic dose (MPD), skin phototype, and clinical progression.
  5. Positioning the patient safely inside the UVA phototherapy cabin or directing targeted UVA units to specific anatomical areas.
  6. Administration of the calibrated UVA light dose under direct clinical supervision.
  7. Post-treatment evaluation and provision of strict instructions for the patient to avoid natural sunlight and wear UVA-protective sunglasses for 12 to 24 hours post-ingestion.
  8. Thorough documentation of the psoralen dosage and route, exact UVA dose, duration of exposure, and any observed adverse reactions.

Coding Guidelines

  • CPT 96912 specifically describes PUVA (psoralens and UVA) and should not be used for UVB therapy with tar or petrolatum (which is reported with CPT 96910) or standard actinotherapy (reported with CPT 96900).
  • The supply of the oral psoralen medication is typically billed separately (e.g., using an appropriate HCPCS J-code or via direct prescription to the pharmacy), whereas the topical application might have payer-specific coverage rules.
  • Evaluation and Management (E/M) services are not separately reported on the same day as 96912 unless a significantly distinct, separately identifiable service is performed, requiring modifier 25.
  • Routine evaluation of the patient's skin to determine the UVA dose for that session is an inclusive component of 96912 and does not justify an independent E/M code.
  • Do not report CPT 96912 in conjunction with CPT 96913 (severe photoresponsive dermatoses requiring 4-8 hours of care) for the same treatment session.

Associated ICD-10 Codes